Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the applications and potential of Bioengineered Artificial Skin Substitutes in cosmetics and pharmacology research, with no new clinical findings reported.

In this retrospective study, baricitinib and ritlecitinib showed similar effectiveness and safety over 52 weeks for treating severe alopecia areata, with non-severe adverse events more common for baricitinib, driven by weight gain.

CaBP1 and 2 are important for maintaining the activity of calcium channels necessary for hearing in inner ear cells.

This study investigated the safety and efficacy of IV iron maltoside 1000 in treating iron-deficiency anemia among children with IBD and found a significant increase in hemoglobin levels by 6 weeks, maintained for up to a year, with minimal side effects reported.

This study found that Janus Kinase inhibitors, tofacitinib and baricitinib, showed effectiveness and safety in treating severe alopecia areata in a real-world setting, with optimal tolerability noted in younger individuals.

This article discusses frontal fibrosing alopecia as a type of Lichen planopilaris marked by gradual hair loss at the front of the scalp but reports no new clinical results.

This case report highlights significant improvement in a patient with severe alopecia areata who responded well to ivarmacitinib after a suboptimal response to another JAK inhibitor, tofacitinib, suggesting ivarmacitinib as a potential alternative for tofacitinib-refractory cases.

This study found that vibration assisted analgesia reduced pain during intralesional corticosteroid therapy for hair loss, enabling treatment in a broader range of patients, including those with needle phobia.

This case study reports that a woman with epidermolysis bullosa acquisita experienced severe cicatricial alopecia and total nail loss after discontinuing treatment for two years, highlighting the potential for serious effects if the condition is not managed.

In this study, researchers found that patients with severe alopecia areata who respond to baricitinib treatment within six months may improve clinically within a year, while those with very severe disease may require at least a year for evidence of treatment effect.

In in-vitro experiments, this study found that poncirin showed higher inhibitory activity against JAK3 than tofacitinib, suggesting potential for alopecia areata treatment.

This article discusses the formation and membership of the British Association of Hair Restoration Surgeons and reports no clinical findings.

This study found that tofacitinib and baricitinib, when administered with unorthodox weight-stratified dosing in pediatric patients with moderate-to-severe AA, showed comparable efficacy and tolerability, though baricitinib's efficacy decreased with non-standard dosing.

This study observed that atopic dermatitis severity was associated with higher eosinophil counts and FLG variants, suggesting distinct endotypes that may require tailored treatment approaches.

This case study reports a young male with alopecia universalis experienced significant hair whitening following baricitinib treatment, highlighting the need for further research on JAK inhibitors' impact on hair pigmentation and their underlying mechanisms.

Electrical impedance spectroscopy improves biopsy accuracy and efficiency for skin lesions.

This study suggests that icariin promotes hair follicle growth in mice by enhancing IGF-1 expression in dermal papilla cells.

This article highlights the rising interest in Janus kinase inhibitors for alopecia areata, especially following the FDA approval of baricitinib, underscoring the need for better patient education and physician guidance in selecting appropriate treatments for hair loss.

This study identified that dominant mutations in the KLHL24 gene cause epidermolysis bullosa through dysregulated autoubiquitination, leading to excessive degradation of keratin 14.

This case study reports a previously undescribed cause of drug-induced autoimmune hepatitis triggered by para-aminobenzoic acid (PABA), emphasizing the need for caution with this supplement.

This study found that patients with kerion responded well to antifungal treatments, with a lower dose of prednisolone effectively reducing inflammation when systemic corticosteroids were needed.

This guideline outlines therapies for hidradenitis suppurativa/acne inversa, noting that oral tetracyclines, clindamycin, and surgical options are important for treatment, with adalimumab, secukinumab, and bimekizumab also approved.

This study found that Ficus benghalensis leaf extracts reduced the activity of 5 α-reductase II and promoted hair growth in rabbits by elongating the hair follicle's anagen phase, suggesting potential for treating hair loss.

This study estimates that adding baricitinib to a commercial formulary for treating severe alopecia areata would slightly increase the budget by $1,383,345 over five years, with minimal impact per member per month.

This article discusses a case study supporting the reclassification of KID syndrome as an ectodermal dysplasia, introducing a potential treatment combination that may alleviate symptoms in affected patients.

This study found that a community education program using group discussions and leaflets significantly increased knowledge and skills among Sungai Bilu residents in South Kalimantan for using riverbank plants as alternative medicine.

This study found that a hydrogel containing icariin enhanced wound healing and hair-follicle regeneration in vivo by promoting M2 macrophage polarization and modulating the BMP pathway, with treated skin defects showing improved recovery and new hair follicle development compared to untreated defects.

This review summarized the latest knowledge suggesting that Janus kinase inhibitors may have therapeutic potential for treating skin diseases like atopic dermatitis and psoriasis, especially when conventional therapies do not work.

This study described a case where both alopecia universalis and Crohn's ileitis in a 23-year-old man showed remarkable improvement with the JAK1 inhibitor upadacitinib, highlighting its potential as a treatment for patients with concurrent conditions.